Smith TR, Spierings ELH, Cady R, et al. - In this integrated analysis, researchers sought to assess the comprehensive safety and tolerability of eptinezumab across a broad spectrum of patients with migraine using trial data from the eptinezumab clinical development program. Data from four randomized, double-blind, placebo-controlled studies and the first year of one open-label study were pooled. The sample consisted of 2,867 patients with migraine who received at least 1 dose of eptinezumab (n = 2,076) or placebo (n = 791). In the individual treatment cohorts, the majority of treatment-emergent adverse events were mild to moderate in severity and considered unrelated to study drug. According to findings, the intravenous administration of eptinezumab every 12 weeks in adults with migraine demonstrated a favorable safety and tolerability profile.